Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic...

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III <br />RESONATETM Trial

Presented By John Byrd at 2014 ASCO Annual Meeting

Background

Presented By John Byrd at 2014 ASCO Annual Meeting

RESONATE™ Phase 3 Study Design

Presented By John Byrd at 2014 ASCO Annual Meeting

Study Objectives

Presented By John Byrd at 2014 ASCO Annual Meeting

Inclusion Criteria

Presented By John Byrd at 2014 ASCO Annual Meeting

Patient Disposition

Presented By John Byrd at 2014 ASCO Annual Meeting

Baseline Characteristics

Presented By John Byrd at 2014 ASCO Annual Meeting

Progression-Free Survival

Presented By John Byrd at 2014 ASCO Annual Meeting

Progression-Free Survival by Baseline Characteristics and Molecular Features

Presented By John Byrd at 2014 ASCO Annual Meeting

Overall Survival

Presented By John Byrd at 2014 ASCO Annual Meeting

Overall Response to Therapy: <br />IRC and Investigator Assessment

Presented By John Byrd at 2014 ASCO Annual Meeting

Best IRC Response without Second CT Confirmation

Presented By John Byrd at 2014 ASCO Annual Meeting

Safety: Adverse Events (≥15%) Regardless of Attributiona

Presented By John Byrd at 2014 ASCO Annual Meeting

Safety Overview

Presented By John Byrd at 2014 ASCO Annual Meeting

Safety: Atrial Fibrillation and Bleeding-Related Adverse Events

Presented By John Byrd at 2014 ASCO Annual Meeting

Conclusions

Presented By John Byrd at 2014 ASCO Annual Meeting

Acknowledgments

Presented By John Byrd at 2014 ASCO Annual Meeting

Acknowledgments

Presented By John Byrd at 2014 ASCO Annual Meeting